Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4277651
Max Phase: Preclinical
Molecular Formula: C26H42N4O7
Molecular Weight: 522.64
Molecule Type: Small molecule
Associated Items:
ID: ALA4277651
Max Phase: Preclinical
Molecular Formula: C26H42N4O7
Molecular Weight: 522.64
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: C[C@@]12CC[C@@H]3[C@@](CC[C@H]4[C@@]3(C)CCC[C@@]4(C)C(=O)O[C@@H]3O[C@H](C(=O)NN)[C@@H](O)[C@H](O)[C@H]3O)(C/C1=N\N)C2
Standard InChI: InChI=1S/C26H42N4O7/c1-23-9-5-14-24(2)7-4-8-25(3,13(24)6-10-26(14,12-23)11-15(23)29-27)22(35)37-21-18(33)16(31)17(32)19(36-21)20(34)30-28/h13-14,16-19,21,31-33H,4-12,27-28H2,1-3H3,(H,30,34)/b29-15+/t13-,14-,16-,17-,18+,19-,21-,23-,24+,25+,26-/m0/s1
Standard InChI Key: DLZVOYLBPPAIDX-FLKRVDGSSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 522.64 | Molecular Weight (Monoisotopic): 522.3053 | AlogP: 0.44 | #Rotatable Bonds: 3 |
Polar Surface Area: 189.72 | Molecular Species: NEUTRAL | HBA: 10 | HBD: 6 |
#RO5 Violations: 2 | HBA (Lipinski): 11 | HBD (Lipinski): 8 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 11.65 | CX Basic pKa: 3.97 | CX LogP: 1.17 | CX LogD: 1.17 |
Aromatic Rings: 0 | Heavy Atoms: 37 | QED Weighted: 0.13 | Np Likeness Score: 2.00 |
1. Wang M, Li H, Xu F, Gao X, Li J, Xu S, Zhang D, Wu X, Xu J, Hua H, Li D.. (2018) Diterpenoid lead stevioside and its hydrolysis products steviol and isosteviol: Biological activity and structural modification., 156 [PMID:30059803] [10.1016/j.ejmech.2018.07.052] |
2. Sharipova RR, Belenok MG, Garifullin BF, Sapunova AS, Voloshina AD, Andreeva OV, Strobykina IY, Skvortsova PV, Zuev YF, Kataev VE.. (2019) Synthesis and anti-cancer activities of glycosides and glycoconjugates of diterpenoid isosteviol., 10 (8): [PMID:31673312] [10.1039/C9MD00242A] |
Source(1):